# Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

> **NCT00933985** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 22 (actual)

## Conditions studied

- Acute Leukemias of Ambiguous Lineage
- Acute Undifferentiated Leukemia
- Angioimmunoblastic T-cell Lymphoma
- Blastic Phase Chronic Myelogenous Leukemia
- Childhood Burkitt Lymphoma
- Childhood Chronic Myelogenous Leukemia
- Childhood Diffuse Large Cell Lymphoma
- Childhood Immunoblastic Large Cell Lymphoma
- Childhood Nasal Type Extranodal NK/T-cell Lymphoma
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Hepatosplenic T-cell Lymphoma
- Intraocular Lymphoma
- Noncutaneous Extranodal Lymphoma
- Peripheral T-cell Lymphoma
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Hairy Cell Leukemia
- Relapsing Chronic Myelogenous Leukemia
- Small Intestine Lymphoma
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** dexrazoxane hydrochloride
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** obatoclax mesylate
- **DRUG:** liposomal vincristine sulfate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00933985
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-06
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00933985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00933985, "Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00933985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*